Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogenic umbilical cord-derived mesenchymal stem cell
- Development stage
- Unknown
- Lead developer
- Medipost
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular, Intravenous, Intrathecal, Intradermal
01
Overview
Allogenic umbilical cord-derived mesenchymal stem cells (UC-MSCs) are multipotent stromal cells isolated from the Wharton's jelly or blood of donated human umbilical cords. These cells possess the ability to differentiate into chondrogenic, osteogenic, and adipogenic lineages and exhibit immunomodulatory, anti-inflammatory, and regenerative properties. UC-MSCs are hypoimmunogenic due to low expression of HLA class II molecules and lack hematopoietic markers such as CD34. They have been investigated in clinical trials for a range of indications including cartilage repair in osteoarthritis, treatment of full-thickness cartilage defects, recessive dystrophic epidermolysis bullosa (RDEB), amyotrophic lateral sclerosis (ALS), cerebral palsy, and inflammatory bowel disease. The mechanism of action is primarily through paracrine signaling that modulates immune responses and promotes tissue regeneration rather than direct engraftment or differentiation[1][2][4][7].
- Brand names
- AlloRxCellistem
- Other names
- allogeneic umbilical cord-derived mesenchymal stem cellallogeneic umbilical cord blood–derived mesenchymal stem cellhuman umbilical cord blood–derived mesenchymal stem cell
Beyond the preview
Go deeper on allogenic umbilical cord-derived mesenchymal stem cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogenic umbilical cord-derived mesenchymal stem cell.